Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Van Herk Investments B.V. on 15 January 2018.
Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Marshall Wace LLP on 12 January 2018.
Bio Analytical Research Corporation (BARC), the global central laboratory division of Cerba HealthCare, today announces that Biogazelle will join the pool of expert laboratories they consistently collaborate with.
In the Belgian biotech space, 2018 has started with a bang. With not even two full weeks into the new year, two Belgian biotechs have already received takeover bids from major pharma players. While Takeda and Tigenix seem to be aligned when it comes to the takeover story, Danish diabetes specialist Novo Nordisk appears to be having a more difficult time convincing its target of choice, Ablynx.
TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the antiinflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, announces today that the 52-week results of the Phase III ADMIRE-CD trial investigating Cx601 (darvadstrocel) have been published in Gastroenterology1.
Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.
Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.
Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.
The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.
Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.
VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.
imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.
Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes.